Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway
Jenny Xie, … , Shunichi Takeda, Alan D. D’Andrea
Jenny Xie, … , Shunichi Takeda, Alan D. D’Andrea
Published March 9, 2015
Citation Information: J Clin Invest. 2015;125(4):1523-1532. https://doi.org/10.1172/JCI79325.
View: Text | PDF
Research Article Oncology

RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway

  • Text
  • PDF
Abstract

The Fanconi anemia/BRCA (FA/BRCA) pathway is a DNA repair pathway that is required for excision of DNA interstrand cross-links. The 17 known FA proteins, along with several FA-associated proteins (FAAPs), cooperate in this pathway to detect, unhook, and excise DNA cross-links and to subsequently repair the double-strand breaks generated in the process. In the current study, we identified a patient with FA with a point mutation in FANCA, which encodes a mutant FANCA protein (FANCAI939S). FANCAI939S failed to bind to the FAAP20 subunit of the FA core complex, leading to decreased stability. Loss of FAAP20 binding exposed a SUMOylation site on FANCA at amino acid residue K921, resulting in E2 SUMO-conjugating enzyme UBC9-mediated SUMOylation, RING finger protein 4–mediated (RNF4-mediated) polyubiquitination, and proteasome-mediated degradation of FANCA. Mutation of the SUMOylation site of FANCA rescued the expression of the mutant protein. Wild-type FANCA was also subject to SUMOylation, RNF4-mediated polyubiquitination, and degradation, suggesting that regulated release of FAAP20 from FANCA is a critical step in the normal FA pathway. Consistent with this model, cells lacking RNF4 exhibited interstrand cross-linker hypersensitivity, and the gene encoding RNF4 was epistatic with the other genes encoding members of the FA/BRCA pathway. Together, the results from our study underscore the importance of analyzing unique patient-derived mutations for dissecting complex DNA repair processes.

Authors

Jenny Xie, Hyungjin Kim, Lisa A. Moreau, Shannon Puhalla, Judy Garber, Muthana Al Abo, Shunichi Takeda, Alan D. D’Andrea

×

Figure 4

The SUMO E3 ligase PIAS1 mediates FANCA SUMOylation at K921.

Options: View larger image (or click on image) Download as PowerPoint
The SUMO E3 ligase PIAS1 mediates FANCA SUMOylation at K921.
(A) Alignme...
(A) Alignment of FANCA from various species. The conserved K921 and I939 residues are indicated with asterisks. (B) 293T cells were transfected with HA-tagged SUMO or cotransfected with HA-tagged SUMO with Myc-tagged FANCAWT. FANCA SUMOylation was determined under denaturing conditions by anti-HA immunoprecipitation, followed by anti-Myc immunoblot. (C) 293T cells were transfected with Myc-tagged FANCAWT or FANCAK921R with HA-SUMO3 as indicated. FANCA SUMOylation was determined under denaturing conditions by anti-HA immunoprecipitation followed by anti-Myc immunoblot. (D) 293T cells were transfected with Myc-tagged FANCAWT or FANCAK921R. Cells were treated with 20 μM MG132 (lanes 2 and 3), and FANCA ubiquitination was examined under denaturing conditions by anti-myc immunoprecipitation, followed by anti-Myc immunoblot. (E) 293T cells were transfected with Myc-tagged FANCAWT alone or with HA-SUMO3 as indicated. Subsequently, cells were exposed to siRNAs against control, UBC9, PIAS1, or PIAS4. Protein expression was determined by immunoblot, and FANCA SUMOylation was examined under denaturing conditions by anti-HA immunoprecipitation, followed by anti-Myc immunoblot. (F) Immunoblot of FANCA derived from cell lysates of the indicated complemented GM6914 cells treated with cycloheximide (CHX) (20 μg/ml). (G) Complemented GM6914 cells were treated with increasing doses of MMC and plated for 4 days. Three independent experiments were performed.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts